Brigitte Michelsen Selected Research

Tumor Necrosis Factor Inhibitors

5/2024	Cut-Offs for Disease Activity States in Axial Spondyloarthritis With Ankylosing Spondylitis Disease Activity Score (ASDAS) Based on C-Reactive Protein and ASDAS Based on Erythrocyte Sedimentation Rate: Are They Interchangeable?
4/2024	Drug effectiveness of 2nd and 3rd TNF inhibitors in psoriatic arthritis - does it depend on the reason for withdrawal from the previous treatment?
1/2024	Patient-Reported Outcomes (PROs) and PRO Remission Rates in 12,262 Biologic-Naïve Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitors in Routine Care.
11/2023	Sex Differences in the Effectiveness of First-Line Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis: Results From the European Spondyloarthritis Research Collaboration Network.
9/2023	Second and third TNF inhibitors in European patients with axial spondyloarthritis: Effectiveness and impact of the reason for switching.
6/2023	Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF inhibitor: results from 13 European registries.
2/2023	Corrigendum to 'Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: data from the EuroSpA collaboration' [Seminars in Arthritis and Rheumatism 56 (2022) 1-13/152081].
1/2023	Is the risk of infection higher during treatment with secukinumab than with TNF inhibitors? An observational study from the Nordic countries.
1/2023	Management of Concomitant Inflammatory Bowel Disease or Uveitis in Patients with Psoriatic Arthritis: An Updated Review Informing the 2021 GRAPPA Treatment Recommendations.
1/2023	One-Third of European Patients With Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor Treatment.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Brigitte Michelsen Research Topics

Disease

19	Psoriatic Arthritis 04/2024 - 01/2017
12	Axial Spondyloarthritis 04/2024 - 01/2020
10	Pain (Aches) 01/2024 - 01/2018
8	Rheumatoid Arthritis 01/2022 - 01/2017
7	Ankylosing Spondylitis 04/2024 - 01/2020
7	Fatigue 01/2024 - 01/2020
4	Arthritis (Polyarthritis) 02/2023 - 01/2022
4	Necrosis 11/2021 - 01/2017
3	Ulcerative Colitis 01/2023 - 01/2021
3	Crohn Disease (Crohn's Disease) 01/2023 - 01/2021
2	Psoriasis (Pustulosis Palmaris et Plantaris) 12/2021 - 01/2021
2	Inflammation (Inflammations) 05/2021 - 11/2020
2	Arthralgia (Joint Pain) 05/2021 - 11/2017
1	Rheumatic Diseases (Rheumatism) 02/2023
1	Non-Radiographic Axial Spondyloarthritis 01/2023
1	Infections 01/2023
1	Uveitis 01/2023
1	Neoplasms (Cancer) 12/2022
1	Spondylarthritis (Spinal Arthritis) 11/2022
1	Acute Coronary Syndrome 01/2022
1	Joint Diseases (Joint Disease) 01/2020

Drug/Important Bio-Agent (IBA)

18	Tumor Necrosis Factor InhibitorsIBA 05/2024 - 01/2020
13	Antirheumatic Agents (DMARD)IBA 01/2023 - 01/2017
7	C-Reactive ProteinIBA 04/2024 - 01/2018
7	secukinumabIBA 01/2024 - 01/2020
4	ametantrone (HAQ)IBA 01/2024 - 10/2022
3	Adalimumab (Humira)FDA Link 01/2023 - 01/2023
2	Prostaglandins AIBA 01/2024 - 11/2022
2	Leukocyte L1 Antigen Complex (Calgranulin)IBA 08/2022 - 05/2021
2	ORALIT (ORS)IBA 01/2022 - 01/2021
2	Infliximab (Remicade)FDA Link 12/2021 - 01/2021
2	1- hydroxy- 5,8- bis(2- ((2- hydroxyethyl)amino)ethylamino)- 9,10- anthracenedioneIBA 05/2021 - 01/2020
2	Methotrexate (Mexate)FDA LinkGeneric 11/2017 - 01/2017
1	Ustekinumab (CNTO 1275)FDA Link 01/2023
1	tofacitinibIBA 01/2023
1	apremilastIBA 01/2023
1	ixekizumabIBA 01/2023
1	Etanercept (Enbrel)FDA Link 01/2023
1	Abatacept (Orencia)FDA Link 01/2023
1	insulin receptor-related receptor (IRR)IBA 12/2022
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 10/2022
1	AntibodiesIBA 08/2022
1	HLA-B27 Antigen (HLA B27 Antigen)IBA 01/2022
1	Interleukin-17 (Interleukin 17)IBA 01/2022
1	Rheumatoid FactorIBA 11/2020
1	Anti-Citrullinated Protein AntibodiesIBA 11/2020
1	golimumab FDA Link 01/2020
1	Acute-Phase Proteins (Acute-Phase Protein)IBA 11/2017

Therapy/Procedure

5	Therapeutics 01/2023 - 11/2020